CN1092049C - 治疗后期过敏反应和炎性疾病的组合物及其用途 - Google Patents

治疗后期过敏反应和炎性疾病的组合物及其用途 Download PDF

Info

Publication number
CN1092049C
CN1092049C CN98808919A CN98808919A CN1092049C CN 1092049 C CN1092049 C CN 1092049C CN 98808919 A CN98808919 A CN 98808919A CN 98808919 A CN98808919 A CN 98808919A CN 1092049 C CN1092049 C CN 1092049C
Authority
CN
China
Prior art keywords
composition
molecular weight
ultra
low molecular
weight heparin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN98808919A
Other languages
English (en)
Chinese (zh)
Other versions
CN1269715A (zh
Inventor
T·阿迈德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tahir Ahmed
Teva Branded Pharmaceutical Products R&D Inc
Ivax Research Holdings Inc
Original Assignee
Baker Cummins Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Cummins Pharmaceuticals Inc filed Critical Baker Cummins Pharmaceuticals Inc
Publication of CN1269715A publication Critical patent/CN1269715A/zh
Application granted granted Critical
Publication of CN1092049C publication Critical patent/CN1092049C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CN98808919A 1997-08-04 1998-08-04 治疗后期过敏反应和炎性疾病的组合物及其用途 Expired - Fee Related CN1092049C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/904,565 1997-08-04
US08/904,565 US5980865A (en) 1995-08-18 1997-08-04 Method for treating late phase allergic reactions and inflammatory diseases

Publications (2)

Publication Number Publication Date
CN1269715A CN1269715A (zh) 2000-10-11
CN1092049C true CN1092049C (zh) 2002-10-09

Family

ID=25419368

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98808919A Expired - Fee Related CN1092049C (zh) 1997-08-04 1998-08-04 治疗后期过敏反应和炎性疾病的组合物及其用途

Country Status (25)

Country Link
US (2) US5980865A (enExample)
EP (1) EP1003479B1 (enExample)
JP (1) JP2001511439A (enExample)
KR (1) KR100551773B1 (enExample)
CN (1) CN1092049C (enExample)
AR (1) AR005221A1 (enExample)
AT (1) ATE323500T1 (enExample)
AU (1) AU8684698A (enExample)
BR (1) BR9811823A (enExample)
CA (1) CA2298445C (enExample)
DE (1) DE69834256T2 (enExample)
DK (1) DK1003479T3 (enExample)
ES (1) ES2260843T3 (enExample)
HU (1) HUP0003013A3 (enExample)
IL (1) IL134230A0 (enExample)
NO (1) NO20000558L (enExample)
NZ (1) NZ502498A (enExample)
PL (1) PL191796B1 (enExample)
PT (1) PT1003479E (enExample)
RU (1) RU2209624C2 (enExample)
SK (1) SK1172000A3 (enExample)
TW (1) TW585771B (enExample)
UA (1) UA75022C2 (enExample)
WO (1) WO1999006025A1 (enExample)
ZA (1) ZA986890B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103269585A (zh) * 2010-10-29 2013-08-28 Opko健康公司 治疗弹性蛋白酶相关病症的超硫酸化双糖

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906153B2 (en) * 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US20050220909A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Composition for protection against superficial vasodilator flush syndrome
US20080153761A1 (en) * 1998-04-08 2008-06-26 Theoharides Theoharis C Compositions for protection against superficial vasodilator flush syndrome, and methods of use
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US6689748B1 (en) * 1998-04-08 2004-02-10 Theoharis C. Theoharides Method of treating mast cell activation-induced diseases with a proteoglycan
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
GB9917092D0 (en) 1999-07-22 1999-09-22 Ml Lab Plc Treatment of angiogenesis-dependent conditions
US20040230559A1 (en) * 1999-08-09 2004-11-18 Mark Newman Information processing device and information processing method
US20040224922A1 (en) * 1999-08-26 2004-11-11 Malcolm King Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
GB0003048D0 (en) * 2000-02-11 2000-03-29 Dealler Stephen F The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism
SE0001631D0 (sv) * 2000-05-04 2000-05-04 Sahltech Ab New use
CA2410577A1 (en) * 2000-05-23 2001-12-13 The Trustees Of Columbia University In The City Of New York Method for treating respiratory disorders associated with pulmonary elastic fiber injury
EP1511466B2 (en) 2002-02-18 2015-02-25 Ockham Biotech Limited Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
WO2003090763A1 (en) * 2002-04-24 2003-11-06 Medicarb Ab Composition and kit for the treatment of inflammatory bowel diseases
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
JPWO2004084918A1 (ja) * 2003-03-25 2006-06-29 積水化学工業株式会社 皮膚止痒外用組成物
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
RU2240801C1 (ru) * 2003-10-02 2004-11-27 Государственное учреждение Научно-исследовательский институт фармакологии Томского научного центра СО РАМН Средство, обладающее противоаллергическим действием
US7923043B2 (en) * 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
CN101010305B (zh) 2004-08-20 2010-08-11 曼金德公司 二酮哌嗪合成的催化反应
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
EP1791555B1 (en) * 2004-09-10 2013-03-13 Pharmaorigin ApS Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
TW200621794A (en) * 2004-10-06 2006-07-01 Akzo Nobel Nv Pulmonary administration of an antithrombotic compound
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
KR101384456B1 (ko) 2005-09-14 2014-04-10 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
US8057840B2 (en) * 2006-01-25 2011-11-15 Tate & Lyle Ingredients Americas Llc Food products comprising a slowly digestible or digestion resistant carbohydrate composition
ES2647080T3 (es) 2006-02-22 2017-12-19 Mannkind Corporation Un método para mejorar las propiedades farmacéuticas de micropartículas que comprenden dicetopiperazina y un agente activo
RU2322987C2 (ru) * 2006-05-23 2008-04-27 Ольга Александровна Субботина Средство для лечения иммунных заболеваний кожи
CN101095693B (zh) * 2006-06-29 2010-10-13 重庆华邦制药股份有限公司 治疗皮炎的复方药物
PT2164501E (pt) * 2007-05-31 2016-06-02 Paradigm Biopharmaceuticals Ltd Xilanos sulfatados para tratamento ou profilaxia de doenças respiratórias
WO2011163272A1 (en) 2010-06-21 2011-12-29 Mannkind Corporation Dry powder drug delivery system and methods
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DK2293833T3 (en) 2008-06-13 2016-05-23 Mannkind Corp DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM
CA2728523C (en) 2008-06-20 2020-03-10 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8551528B2 (en) 2009-06-12 2013-10-08 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9176146B2 (en) * 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
US9050275B2 (en) * 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
MX2012006265A (es) * 2009-12-03 2012-07-25 Opko Health Inc Formulaciones disacaridas hipersulfatadas.
US20110212181A1 (en) * 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
ES2625858T3 (es) 2011-04-01 2017-07-20 Mannkind Corporation Paquete de tipo blíster para cartuchos farmacéuticos
US20120322759A1 (en) * 2011-05-12 2012-12-20 Aventis Pharma Sa Semuloparin for the prevention of venous thromboembolism in cancer patients receiving chemotherapy
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
HUE057140T2 (hu) 2011-12-07 2022-04-28 Allergan Inc Hatásos lipidszállítás humán könny-filmhez sóérzékeny emulziórendszer alkalmazásával
CA3098386C (en) 2012-07-12 2022-11-29 Mannkind Corporation Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
MX369136B (es) 2013-03-15 2019-10-30 Mannkind Corp Composiciones de dicetopiperazina microcristalina y metodos.
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
EP3191091B1 (en) 2014-09-12 2020-08-26 Children's Medical Center Corporation Dietary emulsion formulations and methods for using the same
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
RU2697844C9 (ru) 2014-11-25 2019-10-01 Аллерган, Инк. Стабилизированные композиции для офтальмологического применения, содержащие омега-3-кислоты
TW201815394A (zh) 2016-08-16 2018-05-01 美商歐科製藥有限公司 具有改良口服生物可利用性之純七硫酸化雙醣
JP2020503377A (ja) 2016-12-13 2020-01-30 ベータ セラピューティクス プロプライアタリー リミティド ヘパラナーゼ阻害剤及びそれの使用
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CN114053251A (zh) * 2020-07-29 2022-02-18 苏州融析生物科技有限公司 硫酸化多糖吸入制剂及其在防治新冠病毒相关疾病中的应用
US20220211746A1 (en) * 2021-01-07 2022-07-07 Bionovax Corp. Special heparinoid composition, with repair, prophylactic and anti-inflammatory effects, applied to the lungs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018988A2 (en) * 1993-02-22 1994-09-01 Von Arnim Ulrich Christoph Use of heparins for the treatment of inflammatory or immunological diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3405120A (en) * 1966-01-27 1968-10-08 Green Cross Corp Low molecular chondroitin sulfate and method for manufacturing the same
IT1195497B (it) 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
FR2584606A1 (fr) * 1985-07-12 1987-01-16 Dropic Utilisation de poly- et oligosaccharides pour l'obtention de medicaments actifs dans les pathologies du tissu conjonctif
IT1230582B (it) * 1988-10-21 1991-10-28 Opocrin S P A Lab Farmabiologi Oliogosaccaridi di dermatan solfato ed eparina aventi attivita' antiaterosclerotica
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5032679A (en) 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
ATE217796T1 (de) * 1991-05-02 2002-06-15 Yeda Res & Dev Zusammensetzungen zur verhütung und/oder behandlung von pathologischen prozessen
FR2704861B1 (fr) * 1993-05-07 1995-07-28 Sanofi Elf Fractions d'héparine purifiées, procédé d'obtention et compositions pharmaceutiques les contenant.
US5527785A (en) * 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
SE9303612D0 (sv) * 1993-11-02 1993-11-02 Kabi Pharmacia Ab New use
US5690910A (en) * 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018988A2 (en) * 1993-02-22 1994-09-01 Von Arnim Ulrich Christoph Use of heparins for the treatment of inflammatory or immunological diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MEDLINE EXPRESS:1997339486 1997.6.1 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103269585A (zh) * 2010-10-29 2013-08-28 Opko健康公司 治疗弹性蛋白酶相关病症的超硫酸化双糖
CN103269585B (zh) * 2010-10-29 2016-12-21 Opko健康公司 治疗弹性蛋白酶相关病症的超硫酸化双糖

Also Published As

Publication number Publication date
SK1172000A3 (en) 2001-03-12
IL134230A0 (en) 2001-04-30
RU2209624C2 (ru) 2003-08-10
DK1003479T3 (da) 2006-07-31
PL191796B1 (pl) 2006-07-31
NZ502498A (en) 2002-05-31
WO1999006025A1 (en) 1999-02-11
CN1269715A (zh) 2000-10-11
TW585771B (en) 2004-05-01
DE69834256T2 (de) 2007-02-01
ZA986890B (en) 1999-01-28
US5980865A (en) 1999-11-09
PL338551A1 (en) 2000-11-06
JP2001511439A (ja) 2001-08-14
US6193957B1 (en) 2001-02-27
CA2298445A1 (en) 1999-02-11
EP1003479A4 (en) 2001-01-17
KR100551773B1 (ko) 2006-02-13
BR9811823A (pt) 2000-08-15
NO20000558L (no) 2000-03-14
NO20000558D0 (no) 2000-02-03
EP1003479B1 (en) 2006-04-19
EP1003479A1 (en) 2000-05-31
HUP0003013A2 (hu) 2001-01-29
HUP0003013A3 (en) 2001-11-28
ATE323500T1 (de) 2006-05-15
CA2298445C (en) 2007-07-17
UA75022C2 (en) 2006-03-15
KR20010022533A (ko) 2001-03-15
AR005221A1 (es) 1999-04-28
ES2260843T3 (es) 2006-11-01
AU8684698A (en) 1999-02-22
HK1030370A1 (en) 2001-05-04
PT1003479E (pt) 2006-08-31
DE69834256D1 (de) 2006-05-24

Similar Documents

Publication Publication Date Title
CN1092049C (zh) 治疗后期过敏反应和炎性疾病的组合物及其用途
JP3263723B2 (ja) 喘息を治療するための組成物、及び喘息にかかった患者を治療するための気管支内薬物の製造における超低分子量ヘパリンの使用
JPH06507635A (ja) 病理学的過程の予防および／または治療用組成物
CN1874757A (zh) 治疗肺病的粘液活性剂
CN1329496A (zh) 用于预防药物耐受性的方法和组合物
CN1122108A (zh) 降低呼吸道病理性粘液样内含物的粘滞度的方法
CN1547477A (zh) 具有抗血管生成活性且没有抗凝作用的作为类肝素酶抑制剂的部分脱硫酸化糖胺聚糖衍生物
CN1512885A (zh) 药物组合
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
CN1729007A (zh) 用于预防和治疗炎性疾病,自体免疫性疾病,和移植排斥的组成物及方法
EP1407776B1 (en) A pharmaceutical colloidal preparation comprising hyaluronic acid biopolymers useful in the treatment of respiratory diseases
US7560444B2 (en) Polysaccharides for pulmonary delivery of active agents
US12440488B2 (en) Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension
CN117018018A (zh) 酵母来源β-葡聚糖在制备预防、治疗或辅助治疗旋毛虫病的药物中的应用
KR20100093037A (ko) 폐질환의 건강 관련 삶의 질 부족을 치료하기 위한 흡입용 아즈트레오남 라이신
Kazuhito et al. Suppressive activity of fexofenadine hydrochloride on the production of eosinophil chemoattractants from human nasal fibroblasts in vitro
WO2022171651A1 (en) Novel use of heparin and heparin analogues
CN100421677C (zh) 一种短棒状杆菌制剂或无细胞短棒状杆菌制剂的用途
WO2023277730A1 (ru) Лекарственное средство для профилактики заражения sars-cov-2
HK1069531A (en) Methods and compositions for the prevention of tolerance to medications
CN1418110A (zh) 干燥综合征的治疗剂
HK1053792B (en) Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis
HK1053792A1 (en) Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis
CZ2000426A3 (cs) Farmaceutický přípravek k léčení pozdní fáze alergické reakce a zánětlivé nemoci

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: AHMED TAHIR

Free format text: FORMER OWNER: TEVA BRANDED PHARMACEUTICAL PRODUCTS R + D INC.

Effective date: 20110719

Owner name: TEVA BRANDED PHARMACEUTICAL PRODUCTS R + D INC.

Free format text: FORMER OWNER: TEVA GLOBAL RESPIRATORY RESEARCH LLC

Effective date: 20110719

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: TEVA GLOBAL RESPIRATORY RESEARCH LLC

Free format text: FORMER NAME: IVAX RESEARCH INC.

Owner name: IVAX LABORATORIES INC.

Free format text: FORMER NAME: BAKER NORTON PHARMACEUTICALS INC.

Owner name: IVAX RES INC.

Free format text: FORMER NAME: IVAX LABORATORIES INC.

Owner name: IVAX RESEARCH INC.

Free format text: FORMER NAME: IVAX RES INC.

COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: FLORIDA, THE USA TO: PENNSYLVANIA, THE USA

Free format text: CORRECT: ADDRESS; FROM: THE USA TO: FLORIDA, THE USA

Free format text: CORRECT: ADDRESS; FROM: PENNSYLVANIA, THE USA TO: FLORIDA, THE USA

CP01 Change in the name or title of a patent holder

Address after: American Florida

Patentee after: TEVA global Respiratory Research Ltd.

Address before: American Florida

Patentee before: IVAX Research LLC

Address after: American Florida

Patentee after: IVAX Research LLC

Address before: American Florida

Patentee before: IVAX RESEARCH, Inc.

Address after: American Florida

Patentee after: IVAX Lab Corp.

Address before: American Florida

Patentee before: Baker Norton Pharmaceuticals, Inc.

CP03 Change of name, title or address

Address after: U.S.A.

Patentee after: IVAX RESEARCH, Inc.

Address before: American Florida

Patentee before: IVAX Lab Corp.

TR01 Transfer of patent right

Effective date of registration: 20110719

Address after: American Pennsylvania

Patentee after: TEVA high quality pharmaceutical products R & D Co.

Address before: American Florida

Patentee before: TEVA global Respiratory Research Ltd.

Effective date of registration: 20110719

Address after: American Florida

Patentee after: Tahir Ahmed

Address before: American Pennsylvania

Patentee before: TEVA high quality pharmaceutical products R & D Co.

Effective date of registration: 20110719

Address after: American Florida

Patentee after: IVAX RESEARCH, Inc.

Address before: U.S.A.

Patentee before: IVAX RESEARCH, Inc.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20021009

Termination date: 20170804

CF01 Termination of patent right due to non-payment of annual fee